Living with or without cyclins and cyclin-dependent kinases
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Entry into, progression through, and exit from the G1 phase of the mammalian cell cycle in response to extracellular mitogenic cues are presumed to be governed by cyclin-dependent kinases (Cdks) regulated by the D-type and E-type cyclins. Studies performed over more than a decade have supported the view that these holoenzymes are important, if not required, for these processes. However, recent experiments in which the genes encoding all three D-type cyclins, the two E-type cyclins, cyclin D-dependent Cdk4 and Cdk6, or cyclin E-dependent Cdk2 have been disrupted in the mouse germ line have revealed that much of fetal development occurs normally in their absence. Thus, none of these genes is strictly essential for cell cycle progression. To what extent is the prevailing dogma incorrect, and how can the recent findings be reconciled with past work?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the high frequency of mutations epistatically targeting the RB signaling pathway in cancer cells, inactivation of the individual cyclin D, Cdk4/6, and Ink4a genes in mice, while leading to specific developmental defects when disrupted alone or in combination, established that their functions were nonessential for the cell cycle per se (62-64).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it may well prove that mutations affecting other cell cycle regulators, such as amplification of cyclin E, loss of p27Kip1 or p21Cip1 and activation of CDK2 would bypass the requirement of tumor cells for CDK4/6 activity, thereby also conferring de novo resistance (62-64).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [63]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“…the idea that mutant " cancer stem cells, " rather than their differentiated progeny that may make up the bulk of a tumor, are the only cells strictly responsible for durable tumor maintenance and, in turn, for resistance to therapy (Reya et al. 2001; Taipale and Beachy 2001; Al-Hajj et al. 2003).”
BackgroundStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 2×
“The cells that give rise to many cancers have both the self-renewal and differentiating capacities of tissue stem cells, raising the idea that mutant “cancer stem cells,” rather than their differentiated progeny that may make up the bulk of a tumor, are the only cells strictly responsible for durable tumor maintenance…”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“The AKT kinase controls the subcellular localization of Cip/Kip proteins as well (Liang et al. 2002; Shin et al. 2002; Viglietto et al. 2002), providing yet another avenue for cyclin E–Cdk2 regulation in response to extracellular cues.”
BackgroundSelf-citationA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 2×
“1994); conversely, attenuation of Cdk4 activity by polypeptide inhibitors of the INK4 gene family (Serrano et al. 1993) or by Cdk4-selective drugs (Tetsu and McCormick 2003) results in G1-phase arrest and cell cycle exit.”
BackgroundInhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243 · cited 6×
“1993), and by induction of polypeptide inhibitors of the Cip/Kip family in many physiologic settings (Sherr and Roberts 1995) result in G1-phase arrest.”
BackgroundInfluentialSelf-citationG1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674 · cited 1×
“If this occurs before the G1/S boundary, cells exit the cycle without replicating their DNA, but if it occurs afterward, cells complete mitosis and exit from the cycle in the next G1 interval (Matsushime et al. 1994; Sherr 1994).”
BackgroundSelf-citationCYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259 · cited 3×
“The relevant proteins include three D-type cyclins (D1, D2, and D3) that, in different combinations, bind to, and allosterically regulate, one of two Cdk subunits, Cdk4 and Cdk6, as well as the E-type cyclins (E1 and E2), which, in analogous fashion, govern the activity of a single catalytic subunit, Cdk2 (Morgan 1997…”
BackgroundInfluentialGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 2×
“…GSK-3, an enzyme that is inhibited by the phosphatidylinositol 3-kinase/AKT signaling pathway , in determining the stability of cyclin E implies that its life history, like that of cyclin D1 (Diehl et al. 1998), can be directly influenced by at least one mitogen-dependent kinase signaling cascade.”
BackgroundSelf-citationPolyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954 · cited 1×
“, two potent inhibitors of Cdk2 (Polyak et al. 1994; Reynisdottir et al. 1995; Sherr and Roberts 1995).”
Self-citationCyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614 · cited 2×
“In continuously dividing cells, cyclin D1 exits the cell nucleus during S phase, and its turnover is accelerated throughout this interval (Baldin et al. 1993; Diehl et al. 1998), but Rasdependent cyclin D1 synthesis and its stabilization in G2 phase allow it to reaccumulate before cells divide (Guo…”
Background
Research works printed but not linked: 1
- Resnitzky, D., Gossen, M., Bujard, H., and Reed, S.I. 1994. Ac- celeration of the G1/S phase transition by expression of cy- clins D1 and E with an inducible system. Mol. Cell. Biol. 14: 1669-1679.
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“The synthesis of individual cyclins, and consequent cyclin-dependent kinase (CDK) activation at specific cell cycle stages, coordinates the sequential completion of DNA replication and cell divisio”
BackgroundEmerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
“progression depicted in Figure 1.(77) For example, quiescent, serum-”
BackgroundTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Self-citationRozpedek, W., Pytel, D., Mucha, B., Leszczynska, H., Diehl, J. A., & Majsterek, I. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160523143937 · Cited by 867
“Collectively, exposure of cells to stress conditions and activation of UPR trigger PERK-dependent eIF2α phosphorylation which results in repression of protein translation, involving cyclin D1 – a prominent cell cycle regulator, which plays a key role in controlling G1/S transition [78].”
BackgroundCellular senescence and tumor suppressor gene p16
Rayess, H., Wang, M. B., & Srivatsan, E. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27316 · Cited by 825
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
Satyanarayana, A., & Kaldis, P. (2009) · Oncogene · doi:10.1038/onc.2009.170 · Cited by 774
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Vassilev, L. T., Tovar, C., Chen, S., Knezevic, D., Zhao, X., Sun, H., Heimbrook, D. C., & Chen, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600447103 · Cited by 796
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
“Finally, B-type cyclins (B1 and B2) together with Cdk1 drive cells through mitosis [1,12].”
BackgroundPatnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Ankyrin Repeat: A Unique Motif Mediating Protein−Protein Interactions
Li, J., Mahajan, A., & Tsai, M.-D. (2006) · Biochemistry · doi:10.1021/bi062188q · Cited by 651
Passegué, E., Wagers, A. J., Giuriato, S., Anderson, W. C., & Weissman, I. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050967 · Cited by 646
“In mammals, the rate of cell proliferation is largely determined during the G 1 phase of the cell cycle (6).”
BackgroundPocket proteins and cell cycle control
Cobrinik, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208619 · Cited by 601
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
“Through this interaction, p27 inhibits activation of the cyclin E–Cdk2 and cyclin A–Cdk2 complexes (17, 28).”
BackgroundInfluentialCyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
“In cells, cyclin D1 levels are chiefly regulated by activity of the mitogen-activated protein kinase (MAPK) pathway (which activates CCND1 transcription) and the PI3K pathway (which regulates cyclin D1 protein stability) (Diehl et al., 1998; Sherr and Roberts, 2004).”
Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state
Lin, S.-L., Chang, D. C., Chang-Lin, S., Lin, C.-H., Wu, D. T. S., Chen, D. T., & Ying, S.-Y. (2008) · RNA · doi:10.1261/rna.1162708 · Cited by 451
“It is known that cyclin E-dependent CDK2 is required for the entry of S-phase cell cycle and inhibition of CDK2 results in G1-phase checkpoint arrest, whereas cyclin D1 can override G1-phase arrest in response to DNA damage (Sherr and Roberts 2008).”
BackgroundThe cell cycle in stem cell proliferation, pluripotency and differentiation
Liu, L., Michowski, W., Kolodziejczyk, A., & Sicinski, P. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0384-4 · Cited by 414
Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment
Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E., & Orkin, S. H. (2007) · Cell · doi:10.1016/j.cell.2007.03.055 · Cited by 424
“S phase restriction point (Sherr and Roberts, 2004).”
NFATc1 Balances Quiescence and Proliferation of Skin Stem Cells
Horsley, V., Aliprantis, A. O., Polak, L., Glimcher, L. H., & Fuchs, E. (2008) · Cell · doi:10.1016/j.cell.2007.11.047 · Cited by 424
“Moreover, we find that NFATc1-mediated quiescence involves transcriptional repression of the cyclin dependent kinase 4 gene encoding CDK4, which is required for progression through the G1/ S phase of the cell cycle (Sherr and Roberts, 2004).”
Dewitte, W., Scofield, S., Alcasabas, A. A., Maughan, S. C., Menges, M., Braun, N., Collins, C., Nieuwland, J., Prinsen, E., Sundaresan, V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704166104 · Cited by 410
Signaling Pathways that Control Cell Proliferation
Duronio, R. J., & Xiong, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008904 · Cited by 372
Redox Control of the Cell Cycle in Health and Disease
Sarsour, E. H., Kumar, M. G., Chaudhuri, L., Kalen, A. L., & Goswami, P. C. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2513 · Cited by 381
“Redox regulation of cell-cycle proteins p21, Rb, cyclin D1 = CDK4-6 kinase, and CDC25 phosphatase is observed in NAC-treated mouse and human fibroblasts (37, 175, 279, 288, 340, 351).”
InfluentialDissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R. A., Narita, M., Zhang, M., & Lowe, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.023 · Cited by 388
“However, in addition to the pre-RC components, loss of RB also led to derepression of the cyclin E1 gene (Figures 2C, 4C, and 5A), a key regulator of the cell-cycle engine (Sherr and Roberts, 2004).”
Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.017 · Cited by 379
“Ultimately, the ability of cells to successfully surmount the G1/S restriction point depends upon the integrated effects of various stimuli and suppressors on the enzymatic activities of the critical cyclin-dependent kinases Cdk4 and Cdk2 (Sherr and Roberts, 2004).”
BackgroundThe cell cycle is a redox cycle: Linking phase-specific targets to cell fate
Burhans, W. C., & Heintz, N. H. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.026 · Cited by 361
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
“CDK4 Cyclin D G1 phase epigenetic regulation [19,36,42]”
BackgroundEzhkova, E., Lien, W.-H., Stokes, N., Pasolli, H. A., Silva, J. M., & Fuchs, E. (2011) · Genes & Development · doi:10.1101/gad.2019811 · Cited by 357
“492 GENES & DEVELOPMENT EZH1 and EZH2 repress Ink4b/Ink4a/Arf genes Ink4a and Ink4b encode the p16 and p15 inhibitors of the G1/S phase of the cell cycle, and Arf encodes the p19 inhibitor of the p53 suppressor MDM2 (Sherr and Roberts 2004).”
BackgroundRegulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
AR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
“The sections below first outline reported interactions between AR and cell cycle regulated proteins, and then describe studies that have directly examined AR during the cell cycle.”
InfluentialThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
“In addition, cyclin D-CDK4 and D-CDK6 complexes play a second, noncatalytic function in G1 phase progression through sequestration of cell cycle inhibitors p27Kip1 and p21Cip1, which leads to activation of CDK2-containing complexes (Sherr and Roberts, 2004).”
BackgroundSp1: Emerging roles—Beyond constitutive activation of TATA-less housekeeping genes
Wierstra, I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.074 · Cited by 336
CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
Laurenti, E., Frelin, C., Xie, S., Ferrari, R., Dunant, C. F., Zandi, S., Neumann, A., Plumb, I., Doulatov, S., Chen, J., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.01.017 · Cited by 342
“CDK6 was selected because its mRNA 306 Cell Stem Cell 16, 302–313, March 5, 2015 ª2015 The Authors was consistently upregulated in ST-HSCs both in CB and upon xenotransplantation (Figures 3A, S3A, and S3B), and CDK6/CyclinD complexes regulate G0 exit and early G1 (Sherr and Roberts, 2004).”
InfluentialA function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333
p57 is required for quiescence and maintenance of adult hematopoietic stem cells
Matsumoto, A., Takeishi, S., Kanie, T., Susaki, E., Onoyama, I., Tateishi, Y., Nakayama, K., & Nakayama, K. I. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.06.014 · Cited by 329
Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
Wang, Z. (2021) · Cells · doi:10.3390/cells10123327 · Cited by 287
“According to this model, Cdk4 and/or Cdk6 form complexes with D-type cyclins, which activates Cdk4/6 and initiates phosphorylation of the retinoblastoma protein (Rb) family in early G1 phase [28,29].”
BackgroundDevelopment and function of trophoblast giant cells in the rodent placenta
Hu, D., & Cross, J. C. (2010) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082768dh · Cited by 307
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
Topacio, B. R., Zatulovskiy, E., Cristea, S., Xie, S., Tambo, C. S., Rubin, S. M., Sage, J., Kõivomägi, M., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.020 · Cited by 305
Cell cycle regulation and anticancer drug discovery
Jingwen, B., Yaochen, L., & Guojun, Z. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2017.0033 · Cited by 302
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang, M., Zhang, L., Hei, R., Li, X., Cai, H., Wu, X., Zheng, Q., & Cai, C. (2021) · PubMed Central · Cited by 397
Genome-scale RNAi profiling of cell division in human tissue culture cells
Kittler, R., Pelletier, L., Heninger, A.-K., Slabicki, M., Theis, M., Miroslaw, L., Poser, I., Lawo, S., Grabner, H., Kozak, K., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1659 · Cited by 304
Agirre, X., Vilas-Zornoza, A., Jiménez-Velasco, A., Martin-Subero, J. I., Cordeu, L., Gárate, L., San José-Eneriz, E., Abizanda, G., Rodríguez-Otero, P., Fortes, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4025 · Cited by 302
“Although CDKs are not essential for cell cycle progression (39), it has been well established that inappropriate regulation of CDKs is one of the most frequent alterations in human cancer, making CDKs an attractive target for the development of new inhibitors (40).”
BackgroundSenescence from G2 arrest, revisited
Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability
Fagundes, R., & Teixeira, L. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774845 · Cited by 276
“Importantly, Cyclin E/CDK2 activity is negatively regulated by the KIP/CIP family of CDK inhibitors, p27 and p21, which prevent CDK2 activation by CAK phosphorylation and also inhibit Cyclin E/CDK2 complex interaction with substrates (Sherr and Roberts, 2004).”
BackgroundThe Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
“AKT can indirectly affect cyclin D1 expression by phosphorylating and inhibiting the activity of GSK3β, which normally induces cyclin D1 degradation [163].”
BackgroundLeslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2203 · Cited by 285
Kawauchi, T., Chihama, K., Nabeshima, Y.-I., & Hoshino, M. (2006) · Nature Cell Biology · doi:10.1038/ncb1338 · Cited by 273
“Disorganization of these events causes diseases, such as lissencephaly (smooth brain; disruption of cerebral cortical layer structure due to neuronal migration defects) and microcephaly (small brain”
BackgroundThe double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“In normal cells, cyclin D1 is produced in response to extracellular mitogenic signals and the subsequent activation of RAS-dependent signaling cascades, cyclin D1/CDK4/6 complexes assemble, are stabilized and activated (Figure 1(c)) [66].”
BackgroundMYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
“M-phase transition is regulated by CDK1 activated by B-type cyclins (B1 and B2) [43,48].”
BackgroundCDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Scheicher, R., Hoelbl-Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal-Murphy, M., Heller, G., Schneckenleithner, C., Salazar-Roa, M., Zöchbauer-Müller, S., Zuber, J., et al. (2015) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 262
“Progression through the G1 phase of the cell cycle is mediated by activation of the CDK4/6-cyclinD complex and subsequent phosphorylation of the retinoblastoma protein, which triggers E2F-dependent transcription.(1,2) CDK4 and CDK6 show 71% amino acid homology and have been considered to fulfill largely redundant func…”
BackgroundPhosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
“Upon mitogen stimulation or in the late G1 phase, however, RB is hyperphosphorylated at multiple sites by cyclin/CDK complexes such as CYCLIN D/CDK4/6, resulting in release of E2F factors from RB sequestration and progression of the cell cycle (Sherr and Roberts, 2004).”
BackgroundCyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 245
“, growth factors, mitogenic stimuli) cause the release of D-type cyclins (D1, D2, D3) in association with CDK4 and CDK6 initiate further phosphorylation of the retinoblastoma protein family, including pRb, p107, and p130 [10].”
BackgroundGalea, C. A., Wang, Y., Sivakolundu, S. G., & Kriwacki, R. W. (2008) · Biochemistry · doi:10.1021/bi8006803 · Cited by 245
“Many proteins regulate the Cdks, both directly and indirectly, and, in turn, the catalytic activity of the Cdks regulates the activity of myriad downstream targets (51,52).”
BackgroundPilaz, L.-J., Patti, D., Marcy, G., Ollier, E., Pfister, S., Douglas, R. J., Betizeau, M., Gautier, E., Cortay, V., Doerflinger, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909894106 · Cited by 243
“The progression through G1 phase is driven by the sequential kinase activity of cyclin D/cdk4 and cyclin E/cdk2 (24).”
BackgroundMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Regulating DNA Replication in Eukarya
Siddiqui, K., On, K. F., & Diffley, J. F. X. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012930 · Cited by 229
Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell
Yang, K., Hitomi, M., & Stacey, D. W. (2006) · Cell Division · doi:10.1186/1747-1028-1-32 · Cited by 233
“Cell cycle progression ceases following neutralization of cyclin D1 by microinjected antibodies in many cultured cells [4,5], even though knockout studies indicate that many of its functions can be performed by other cyclins during development [ 6-8 ].”
BackgroundCell cycle control in breast cancer cells
Caldon, C. E., Daly, R. J., Sutherland, R. L., & Musgrove, E. A. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20690 · Cited by 238
The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase
Mochizuki, K., Nishiyama, A., Jang, M. K., Dey, A., Ghosh, A., Tamura, T., Natsume, H., Yao, H., & Ozato, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707603200 · Cited by 229
STAT3 controls myeloid progenitor growth during emergency granulopoiesis
Zhang, H., Nguyen-Jackson, H., Panopoulos, A. D., Li, H. S., Murray, P. J., & Watowich, S. S. (2010) · Blood · doi:10.1182/blood-2009-12-259630 · Cited by 232
Takano, M., Lu, Z., Goto, T., Fusi, L., Higham, J., Francis, J., Withey, A., Hardt, J., Cloke, B., Stavropoulou, A. V., et al. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0058 · Cited by 224
Cyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 219
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 206
“CDK1 activation by B-type cyclins promotes transition into M phase [98, 109].”
BackgroundJoshi, I., Minter, L. M., Telfer, J., Demarest, R. M., Capobianco, A. J., Aster, J. C., Sicinski, P., Fauq, A., Golde, T. E., & Osborne, B. A. (2009) · Blood · doi:10.1182/blood-2008-03-147967 · Cited by 213
Besson, A., Gurian-West, M., Chen, X., Kelly-Spratt, K. S., Kemp, C. J., & Roberts, J. M. (2006) · Genes & Development · doi:10.1101/gad.1384406 · Cited by 218
“Moreover, it is unlikely that all p27 translocates into the cytosol in G1 cells (Rodier et al. 2001; Boehm et al. 2002; Ishida et al. 2002; Connor et al. 2003; McAllister et al. 2003; Kamura et al. 2004; Shin et al. 2005).”
BackgroundResultInfluentialSelf-citationA matter of life and death: self‐renewal in stem cells
Fuchs, E., & Chen, T. (2013) · EMBO reports · doi:10.1038/embor.2012.197 · Cited by 207
“As a potent cell cycle inhibitor, p16Ink4a can bind to and in activate the cyclin D–CDK4/6 complex [76].”
The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility
Pandithage, R., Lilischkis, R., Harting, K., Wolf, A., Jedamzik, B., Lüscher-Firzlaff, J., Vervoorts, J., Lasonder, E., Kremmer, E., Knöll, B., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200707126 · Cited by 213
“Correspondence to Bernhard L ü scher: luescher@rwth-aachen.de; or Bernd Kn ö ll: bernd.knoell@uni-tuebingen.de R. Pandithage ’ s present address is Leica, 1170 Wien, Austria.”
BackgroundCyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S.-I., Choi, Y., Kondratiuk, I., Silver, D. P., Wolgemuth, D. J., Akashi, K., & Sicinski, P. (2009) · Cell · doi:10.1016/j.cell.2009.04.062 · Cited by 215
“In contrast, mice lacking particular G1 cyclins or Cdks displayed normal proliferation in the overwhelming majority of cell types and presented only narrow, tissue-specific abnormalities (Sherr and Roberts, 2004; Li et al., 2009; Malumbres and Barbacid, 2009).”
BackgroundInfluentialKhang, D., Choi, J., Im, Y.-M., Kim, Y.-J., Jang, J.-H., Kang, S. S., Nam, T.-H., Song, J., & Park, J.-W. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.005 · Cited by 208
Sarkar, S., Dey, B. K., & Dutta, A. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-01-0062 · Cited by 204
“Here, however, the loss of cdk2 is believed to be compensated for by other cdk genes (Sherr and Roberts, 2004).”
P16INK4A—More Than a Senescence Marker
Safwan-Zaiter, H., Wagner, N., & Wagner, K.-D. (2022) · Life · doi:10.3390/life12091332 · Cited by 181
“P16 binding to CDK 4/6 can directly inhibit their activities in addition to non-p16 CDK inhibitors such as p27 for further hypophosphorylation of pRB (Figure 2) [64].”
BackgroundTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
The rules of disorder or why disorder rules
Gsponer, J., & Madan Babu, M. (2009) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2009.03.001 · Cited by 199
A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation
Okabe, H., Lee, S.-H., Phuchareon, J., Albertson, D. G., McCormick, F., & Tetsu, O. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000128 · Cited by 198
The A-Type Cyclin CYCA2;3 Is a Key Regulator of Ploidy Levels in Arabidopsis Endoreduplication
Imai, K. K., Ohashi, Y., Tsuge, T., Yoshizumi, T., Matsui, M., Oka, A., & Aoyama, T. (2006) · The Plant Cell · doi:10.1105/tpc.105.037309 · Cited by 191
“;3 and the other A2-type genes are active, A2-type cyclins are supposed to have some of the canonical cyclin A functions known in the mitotic cell cycle of animals (for review, see Sherr and Roberts, 2004).”
BackgroundTrastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13143540 · Cited by 173
“Moreover, the phosphorylation of the retinoblastoma (RB) protein by the cyclin D-CDK4/6 complex blocks the association of RB and E2F transcription factor, which leads to the activation of E2F-modulated transcription of genes necessary for the entry of the cells into the S phase of the cell cycle, wherein the DNA stran…”
BackgroundBiochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 185
“Cdk2 promotes phosphorylation of Rb on specific sites, thereby reversing its ability to sequester E2F.(64) Cdk2-mediated phosphorylation of Rb also impacts the interactions of Rb with histone deacetylases and other chromatin remodeling proteins.”
BackgroundRegulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway
Kent, D., Copley, M., Benz, C., Dykstra, B., Bowie, M., & Eaves, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5134 · Cited by 181
Role of CDK/cyclin complexes in transcription and RNA splicing
LOYER, P., TREMBLEY, J., KATONA, R., KIDD, V, & LAHTI, J. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.02.005 · Cited by 186
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
“Cyclin D:CDK4/6 are thought to form ternary complexes that bind cyclin-dependent kinase inhibitors (CDKIs) of the p21Cip/p27Kip1 family (Sherr and Roberts, 2004).”
G1 to S phase cell cycle transition in somatic and embryonic stem cells
Neganova, I., & Lako, M. (2008) · Journal of Anatomy · doi:10.1111/j.1469-7580.2008.00931.x · Cited by 170
“Downregulation of Cdk2 strongly inhibits proliferation of MEFs lacking all three D-type cyclins (Kozar et al. 2004), suggesting that Cdk2 might substitute for the lack of cyclin D/Cdkdependent kinase activity during mouse development (Sherr & Roberts, 2004).”
BackgroundRapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Arora, M., Moser, J., Hoffman, T. E., Watts, L. P., Min, M., Musteanu, M., Rong, Y., Ill, C. R., Nangia, V., Schneider, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.013 · Cited by 166
Many forks in the path: cycling with FoxO
Ho, K. K., Myatt, S. S., & Lam, E. W.-F. (2008) · Oncogene · doi:10.1038/onc.2008.23 · Cited by 169
Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates
Suryadinata, R., Sadowski, M. C., & Šarčević, B. (2010) · Bioscience Reports · doi:10.1042/bsr20090171 · Cited by 213
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167
“Several studies have recently shown that most cell cycle kinases are not essential for cell survival in vitro and in vivo (14).”
BackgroundJohnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
The Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis
Wagner, K.-D., & Wagner, N. (2022) · Cells · doi:10.3390/cells11121966 · Cited by 156
Intrinsic Regulators of Pancreatic β-Cell Proliferation
Heit, J. J., Karnik, S. K., & Kim, S. K. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104425 · Cited by 165
Cyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
“Unlike other cyclins, the early G1 D-type cyclin family is mostly regulated by mitogen induced signal transduction pathways, which not only promote their synthesis but subsequently control: a) their activity by modulating cyclin D translation and stability, b) their assembly with the Cdk partners Cdk4 and Cdk6, and c)…”
BackgroundThe Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Ali, S., Heathcote, D. A., Kroll, S. H. B., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0301 · Cited by 161
“Hence, cells from mice that have been ablated for CDK2 are able to cycle, and CDK2 / mice are viable (14, 15).”
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“These initial kinetic studies suggest that cyclin Ds–CDK4/6 and cyclin Es–CDK2 cooperatively control G1 progression in mammalian cells, a notion that is both supported and expanded by the subsequent analyses in genetically targeted mutant mice (Sherr and Roberts, 2004).”
BackgroundPhosphorylation network dynamics in the control of cell cycle transitions
Fisher, D., Krasińska, L., Coudreuse, D. Y. M., & Novák, B. (2012) · Journal of Cell Science · doi:10.1242/jcs.106351 · Cited by 171
“Cdk1 is activated by binding one of several cyclins that are sequentially expressed during the cell cycle (Sherr and Roberts, 2004), and directly through Cdk-activating kinase (CAK)-mediated phosphorylation of its conserved kinase-activation loop (Russo et al., 1996).”
BackgroundLiu, P., Kao, T. P., & Huang, H. (2008) · Oncogene · doi:10.1038/onc.2008.104 · Cited by 158
“CDK2 and other G1 CDKs, including CDK4 and CDK6, along with their associated cyclins, are known to be involved in the G1/S transition (Sherr and Roberts, 2004).”
BackgroundCell cycle in mouse development
Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208608 · Cited by 172
Metadata
- Authors
- Sherr, C. J., & Roberts, J. M.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-11-15
- Volume
- 18
- Issue
- 22
- Pages
- 2699-2711
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2152107294
- Cited by
- 1,089
- References
- 115
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 48 · 2023: 38 · 2022: 34 · 2021: 42 · 2020: 49 · 2019: 50 · 2018: 36 · 2017: 35 · 2016: 42 · 2015: 51 · 2014: 47 · 2013: 52 · 2012: 62
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- cyclin-dependent kinases, cyclins, D-type cyclins, G1 phase, cell cycle progression, CDK4, CDK6, CDK2, cyclin E, cyclin D, fetal development, mitogenic signaling
- MeSH terms
- Animals, Cell Cycle, Humans, Signal Transduction, Cyclins, Mice, Knockout, Cyclin-Dependent Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.